XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Share-Based Compensation - Summary of the Option Unit Activity (Details)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected weighted average period 3 years 6 months
2021 Equity Plan [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 3,714,540
Number of units, granted | shares 42,950
Number of units, grant outstanding ending balance | shares 3,757,490
Number of grants, vested | shares 966,835
Number of grants, unvested | shares 2,790,655
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 15.33
Weighted average exercise price, exercised | $ / shares 16.85
Weighted average exercise price, grant outstanding ending balance | $ / shares 15.35
Weighted average exercise price, grants vested | $ / shares 15.00
Weighted average exercise price, grants unvested | $ / shares $ 15.47
Weighted Average Remaining Contractual Term, grants outstanding 9 years 3 months 18 days
Expected weighted average period 9 years 2 months 12 days
Aggregate Intrinsic Value, grants outstanding | $ $ 18.2
Aggregate Intrinsic Value, grants vested | $ $ 5.0
First Advantage Corporation [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 3,519,563
Number of grants, exercised | shares (76,968)
Number of grants, forfeited | shares 0
Number of units, grant outstanding ending balance | shares 3,442,595
Number of grants, vested | shares 933,896
Number of grants, unvested | shares 2,508,699
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 6.66
Weighted average exercise price, exercised | $ / shares 6.75
Weighted average exercise price, forefeited | $ / shares 0
Weighted average exercise price, grant outstanding ending balance | $ / shares 6.66
Weighted average exercise price, grants vested | $ / shares 6.64
Weighted average exercise price, grants unvested | $ / shares $ 6.67
Weighted Average Remaining Contractual Term, grants outstanding 7 years 10 months 24 days
Expected weighted average period 7 years 10 months 24 days
Aggregate Intrinsic Value, grants outstanding | $ $ 46.6
Aggregate Intrinsic Value, grants vested | $ $ 12.7